Background {#Sec1}
==========

Hepatitis C virus (HCV) infection remains an important world-wide health concern with 130 -- 150 million people infected \[[@CR1]\]. Approximately 75--85% of HCV-infected persons will progress to chronic HCV infection and are at risk for the development cirrhosis, and hepatocellular carcinoma (HCC) \[[@CR2]\]. Most people infected with HCV are asymptomatic but the risk of HCC is substantially higher in HCV infected patients compared to HCV negative subjects \[[@CR3]\]. The CDC estimates that 1 -- 5% of those chronically infected with HCV will die from end stage liver disease due to either cirrhosis or hepatocellular carcinoma \[[@CR4]\].

Recently developed direct acting antiviral treatments for HCV can eliminate the virus from almost all patients \[[@CR5]\]. The elimination of HCV is measured by a sustained virological response (SVR). SVR is defined as an undetectable HCV RNA plasma/serum concentration at 12 or 24 weeks after treatment completion using a sensitive HCV RNA quantitation assay with a limit of quantitation of under 25 IU/ml \[[@CR6]\]. The risks of HCC and mortality are reduced in patients achieving SVR compared to the risks in untreated patients \[[@CR7]\].

CDC, AASLD/IDSA and EASL guidelines recommend the use of quantitative HCV RNA testing for pre-treatment and on-treatment patient monitoring and management. Quantitative HCV nucleic acid amplification test (NAAT) results prior to initiating HCV therapy are used to determine the baseline level of viral load, and these results guide decisions for treatment regimens and durations \[[@CR6], [@CR8], [@CR9]\]. For diagnosing HCV infections, CDC and AASLD/IDSA recommend initial testing with an HCV antibody test (anti-HCV test). A positive HCV antibody test result is indicative of an active HCV infection or previous HCV infection. An HCV NAAT is recommended to confirm the presence of an active HCV infection or reinfection, after previous viral clearance, in a patient following a positive HCV antibody test result \[[@CR6], [@CR8]\]. In addition, HCV NAAT testing is also recommended for patients with negative antibody results, if they are immunocompromised or have been exposed to the Hepatitis C virus within last six months. EASL recommends the use of a sensitive molecular test for HCV RNA for the diagnosis of HCV infection \[[@CR9]\].

During HCV therapy, HCV quantitative assays are important tools for determining the effectiveness of HCV treatment. Guidelines from the AASLD and EASL suggest testing HCV RNA not only at baseline, but also periodically during treatment (i.e., 4, 12 weeks) and at completion of treatment (i.e., 8 or 12 weeks) and post-treatment (i.e., 12 or 24 weeks); \[[@CR6], [@CR9], [@CR10]\].

This paper presents the data from studies using the Aptima HCV Quant Dx (Aptima; Hologic, Inc., San Diego, CA, USA) assay. This is a quantitative HCV RNA assay for monitoring and diagnosing of HCV infection on the fully automated Panther system. The Aptima assay uses real-time transcription-mediated amplification (TMA) to amplify the RNA target (5'-UTR) of HCV genotypes 1 to 6 \[[@CR11]\]. The assay uses a negative and two positive controls to validate accuracy of the results. The assay has a dynamic range of 10 to 100,000,000 IU/mL and uses 500uL of serum or plasma in each reaction. Performance characteristics tested include 95% limit of detection (LoD), lower limit of quantitation (LLoQ), equal genotype detection, linearity precision and specificity. The results of clinical specimens tested with the Aptima assay were compared to those results obtained by the Abbott and Roche assays.

Methods {#Sec2}
=======

Linearity {#Sec3}
---------

The linear range of the Aptima assay was demonstrated by testing panels of HCV armored RNA or clinical specimens diluted in HCV negative human plasma and serum. Panels ranged in concentration from 8.08 log IU/mL to less than 1 log IU/mL. Armored RNA was used to make panels above 6 log IU/mL. A combination of diluted clinical specimens or armored RNA was used to make lower concentrations panels.

Analytical Sensitivity (Limit of Detection, LoD) {#Sec4}
------------------------------------------------

The LoD was determined by testing dilutions of the WHO 2nd International Standard for Hepatitis C Virus RNA (NIBSC 96/798, genotype 1) in HCV negative human plasma and serum. A total of 10 panel members (0.25, 0.50, 1, 2, 3, 6, 8, 10, 12 and 20 IU/mL) were tested over 3 days on 3 Panther systems with 3 reagent lots for a total of 108 replicates per panel member (36 replicates per lot). In addition, The LoD across genotypes was determined by testing dilutions of HCV positive clinical specimens for genotypes 1, 2, 3, 4, 5 and 6 in HCV negative human plasma and serum. The HCV concentration for each clinical specimen was determined by testing with an FDA approved commercially available HCV quantitative assay. Each panel was tested on three Panther systems over 3 days with 3 reagent lots. A minimum total of 60 replicates were tested for each panel member (minimum 20 replicates per reagent lot). Probit analysis was performed on the Aptima results using SAS software to calculate the LoD for 95% detection rates.

Analytical Sensitivity (Lower Limit of Quantitation, LLoQ) {#Sec5}
----------------------------------------------------------

The LLoQ was determined by testing dilutions of the WHO 2nd International Standard for Hepatitis C Virus RNA (NIBSC 96/798, genotype 1) in HCV negative human plasma and serum. A minimum of 36 replicates of each dilution were tested over 3 days with three reagent lots on 3 Panther systems for a minimum of 108 replicates per dilution. In addition, the LLoQ across genotypes was determined by testing dilutions of HCV positive clinical specimens for genotypes 1, 2, 3, 4, 5 and 6 in HCV negative human plasma and serum. HCV concentration of the clinical specimens was determined using an FDA approved commercially available comparator assay. A minimum of 36 replicates of each dilution were tested over 3 days with each of three reagent lots on 3 Panther systems for a minimum of 108 replicates per panel member. The LLoQ was calculated using a total allowable error of 1 log.

Analytical specificity {#Sec6}
----------------------

Specificity of the Aptima assay was determined using 100 fresh and 270 frozen HCV negative plasma specimens and 98 fresh and 268 frozen HCV negative serum specimens.

Precision {#Sec7}
---------

To assess precision of the Aptima assay, nine positive panel members made by diluting HCV genotype 1a virus and armored RNA into HCV negative plasma were tested in triplicate by one operator using one reagent lot on one Panther systems over 21 test days.

Clinical specimen comparisons {#Sec8}
-----------------------------

Quantitative results for clinical specimens were obtained by running specimens following the manufacturers' instructions. Quantitative results were obtained for 1058 frozen clinical specimens with both the Aptima and Abbott assays. These specimens represent all six HCV genotypes and cover the full dynamic range of both assays. A subset of these specimens was also tested with the Roche assay. From this subset, 611 gave quantitative results with both the Abbott and Roche assays and 608 gave quantitative results with both the Aptima and Roche assays. Three of the 611 specimens gave an invalid result with the Aptima assay, could not be retested and were excluded from the analysis. Thus, the total number of specimens used for the Aptima vs Roche comparison was 608 and for the Abbott vs Roche comparison was 611. Comparable clinical performance of quantitative measurements was demonstrated by linear regression analysis and Bland Altman plots. The genotype distribution as reported by the vendor or lab providing the specimens is shown in Table [1](#Tab1){ref-type="table"}. One hundred and one specimens did not have a genotype.Table 1HCV Specimen Genotype & OriginCountry of OriginTotal nGT 1GT 2GT 3GT 4GT 5GT 6UnknownAlgeria131021Australia33142215Cambodia33Cameroon258512Congo22Egypt162131France8920233016French Guiana11French Polynesia11Gabon918Germany11614Greece4061451917963Guadeloupe211Italy85502438Ivory Coast11Lebanon11Libya11Luxembourg22Madagascar11Martinique11Mauritius11Morocco37141832New Caledonia11Reunion Island11Russia12111Senegal11Spain3420383Thailand33Tunisia2919217Unknown281711USA178361116825100Vietnam3016113Total n10583581262701471937101

Agreement at low HCV Concentrations {#Sec9}
-----------------------------------

One hundred and seven specimens that gave results at or below 25 IU/mL using the Roche assays were compared. For this analysis, results of "Target Not Detected" for Roche or "Not Detected" for Aptima were interpreted as a negative result. A valid result where HCV was detected or quantified was interpreted as a positive result. Both positive and negative agreement between the Aptima assay and the Roche assay was calculated. Where specimens did not agree and sufficient specimen volume was available, the specimen was tested using the Abbott assay.

The specimens using in the studies were obtained as frozen deidentified remnant samples from the following vendors or labs BioCollection, Miami, Florida, USA;Boca Biolistics, Coconut Creek, Florida, USA;Cerba Specimen Services, Saint-Ouen l'Aumone, France;Discovery Life Sciences, Los Osos, California, USA;Hellenic Scientific Society for the Study of AIDS and Transmitted Diseases, Athens, Greece;ProMedDx, Norton, Massachusetts, USA;SeraCare Milford, Massachusetts, USA;SlieaGen, Austin, Texas, USA;Tissue Solutions Glasgow, Scotland;ViroMed Minnetonka, Minnesota, USA

Statistical methods {#Sec10}
-------------------

The 95% positivity rates were estimated using Probit analysis using the normal model and analysis software from the SAS Institute, Cary, NC, USA.

The method comparison simple linear regression and Bland Altman analysis were performed using Analyse-It Software, Leeds, United Kingdom.

Linearity was measured using the R^2^ of the Pearson correlation coefficient calculated using Microsoft Excel (WA, USA).

Results {#Sec11}
=======

Linearity {#Sec12}
---------

As shown in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, the Aptima assay displayed a linear response from less than 1 log IU/mL to 8.08 log IU/mL for genotypes 1, 2, 3, 4, 5 and 6 diluted in plasma and serum. The equations of the linear plots for each genotype are shown in Table [2](#Tab2){ref-type="table"}. The R^2^ values for all the linear fits were 1.00. The slopes ranged from 0.99 to 1.06 and the intercepts from −0.12 to 0.17.Fig. 1Plasma Linearity for the Aptima Assay. Assay linearity for genotypes 1 to 6 was established by diluting armored RNA or HCV positive clinical specimens in HCV negative plasma from 8.08 log IU/mL to below 1 log IU/mL. Armored RNA was used to make panels above 6 log IU/mL. Clinical specimens were used to make lower concentrations with multiple levels of overlapping concentrations for armored RNA and clinical specimen dilutions. The data for the armored RNA dilutions and the clinical specimen dilutions was combined for each genotype to generate the data shown in the figure Fig. 2Serum Linearity for the Aptima Assay. Assay linearity for genotypes 1 to 6 was established by diluting armored RNA or HCV positive clinical specimens in HCV negative serum from 8.08 log IU/mL to below 1 log IU/mL. Armored RNA was used to make panels above 6 log IU/mL. Clinical specimens were used to make lower concentrations with multiple levels of overlapping concentrations for armored RNA and clinical specimen dilutions. The data for the armored RNA dilutions and the clinical specimen dilutions was combined for each genotype to generate the data shown in the figure Table 2Linear Equations for the Plots shown in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}MatrixGenotypeLinear EquationPlasma1y = 1.05x - 0.042y = 0.99x + 0.173y = 1.02x - 0.024y = 1.04x - 0.075y = 1.01x - 0.046y = 1.03x - 0.02Serum1y = 1.05x + 0.002y = 1.06x - 0.123y = 1.02x + 0.054y = 0.99x + 0.095y = 1.00x + 0.046y = 1.05x - 0.11

Analytical sensitivity of Aptima {#Sec13}
--------------------------------

Table [3](#Tab3){ref-type="table"} shows the results of Probit analysis to determine the LoD of HCV genotype 1--6 diluted into either serum or plasma. Three reagent lots were used and the results show the calculated LoD and 95% confidence intervals for each lot separately as well as with all three lots combined. For all genotypes, the calculated LoD was 5 IU/mL or lower. The calculated LLoQ for each HCV genotype is shown in Table [4](#Tab4){ref-type="table"}. The LLoQ varied by genotype from 4 IU/ml for genotype 4 in serum to 10 IU/mL for genotype 6 in serum.Table 3LoD Probit Analysis Results in Plasma and SerumHCV GenotypePlasma - Concentration In IU/mL (95% CI)Serum - Concentration In IU/mL (95% CI)Lot 1Lot 2Lot 33 Lots CombinedLot 1Lot 2Lot 33 Lots Combined1 (WHO)3.32.54.33.42.83.33.93.4(2.5--5.0)(1.9--3.9)(3.3--6.2)(2.9--4.3)(2.1 -- 4.1)(2.5 -- 5.1)(3.1 -- 5.6)(2.9 -- 4.2)22.82.42.72.73.73.34.03.7(2.2--3.9)(1.9--3.4)(2.3--3.5)(2.4--3.2)(3.0--5.3)(2.6--4.9)(3.1--5.8)(3.2--4.5)33.34.33.13.82.72.93.43.0(2.5--5.2)(3.2--6.5)(2.5--4.4)(3.2--4.8)(2.2--3.8)(2.4--4.1)(2.7--5.1)(2.6--3.6)42.72.44.83.51.31.82.31.9(2.2--3.7)(2.0--3.2)(3.9--6.3)(2.7--5.3)(1.0--2.4)(1.4--2.5)(1.7--3.5)(1.6--2.2)52.01.62.12.02.82.23.22.8(1.6--3.1)(1.3--2.4)(1.7--3.1)(1.6--2.6)(2.1--4.9)(1.8--3.5)(2.4--5.3)(2.4--3.6)61.83.92.62.82.23.83.93.4(1.4--2.9)(2.8--6.4)(2.0--3.9)(2.3--3.6)(1.7--3.2)(2.9--5.6)(3.0--5.7)(2.9--4.1) Table 4Summary of LLoQ Results across Genotypes in Plasma and SerumHCV GenotypePlasmaSerumLLoQLLoQLLoQLLoQ(log IU/ml)(IU/ml)(log IU/ml)(IU/ml)1 (WHO)0.8270.93920.7660.80630.8060.67540.8270.65450.8770.72560.7960.9910

Analytical specificity {#Sec14}
----------------------

The results from 370 HCV negative serum and 366 HCV negative plasma specimens are shown in Table [5](#Tab5){ref-type="table"}. Specimens included both fresh and previously frozen specimens. All specimens gave a "Target Not Detected" result for a specificity of 100% (95% confidence intervals 99.2 -- 100% for both serum and plasma).Table 5Specificity for Plasma and Serum SpecimensAptima HCV Quant DxFresh PlasmaFrozen PlasmaPlasma TotalFresh SerumFrozen SerumSerum Total(n)10027037098268366Target Not detected10027037098268366Specificity (95% CI)100%100%100%100%100%100%(97.1--100)(98.9--100)(99.2--100)(97.0--100)(98.9--100)(99.2--100)

Precision {#Sec15}
---------

The CVs for inter-day, inter-run and intra-run and total variation were all below 13.3% (Table [6](#Tab6){ref-type="table"}). In all but one case, the largest component of variation was intra-run or random variation. The exception was for the serum panel at 7.16 IU/mL where the intra-run variation was 0.55% but the inter-operator variation and inter-lot variation were 0.70 -- 0.73% respectively.Table 6Precision of the Aptima AssayMatrixN^a^Mean Concentration (log IU/mL)Inter-OperatorInter-InstrumentInter-LotInter-RunIntra-RunTotalSDCV (%)SDCV (%)SDCV (%)SDCV (%)SDCV (%)SDCV (%)Plasma981.230.000.000.000.000.043.350.064.540.129.840.1411.34Plasma1622.060.000.000.052.230.073.200.031.470.104.910.146.88Plasma1623.020.010.240.030.890.041.470.010.330.093.080.113.77Plasma1624.870.000.000.000.000.030.600.040.860.061.130.102.04Plasma1627.160.010.200.020.210.040.520.000.000.050.750.091.27Serum1321.270.000.000.000.000.075.160.000.000.1512.170.1713.31Serum1622.170.041.710.020.990.073.010.052.150.083.530.125.61Serum1623.090.000.000.020.670.061.790.030.900.072.260.113.44Serum1614.860.040.780.000.000.081.670.000.000.081.720.132.65Serum1627.160.050.700.000.000.050.730.020.310.040.550.101.35^a^Number of valid results within range of the assay

Clinical specimen comparisons {#Sec16}
-----------------------------

Testing clinical specimens with the Aptima, Abbott and Roche assays allowed a three-way comparison of assay performance to be made. Quantifiable results with both the Aptima and Abbott assays were obtained for 1058 HCV clinical specimens. Linear regression analysis yielded a slope of 1.06 (95% CI: 1.05 to 1.07), intercept of 0.08 (95% CI: 0.03 to 0.13), and R^2^ of 0.98 (Fig. [3](#Fig3){ref-type="fig"}, Additional file [1](#MOESM1){ref-type="media"}). The slope and intercept were statistically significant (*p* \< 0.0001 and *p* = 0.002 respectively). By Bland-Altman analysis (Fig. [4](#Fig4){ref-type="fig"}), the average bias was 0.34 log IU/mL with 95% acceptability limits of −0.20 to 0.88 log IU/mL. Quantifiable results with both the Aptima and Roche assays were obtained for 608 HCV positive clinical specimens. Linear regression analysis yielded a slope of 1.05 (95% CI: 1.03 to1.07), intercept of 0.12 (95% CI: −0.20 to −0.04), and R^2^ of 0.96 (Fig. [5](#Fig5){ref-type="fig"}, Additional file [1](#MOESM1){ref-type="media"}). The slope and intercept were statistically significant (*p* \< 0.0001 and *p* = 0.003 respectively). By Bland-Altman analysis (Figure [6](#Fig6){ref-type="fig"}), the average bias was 0.11 log IU/mL with 95% acceptability limits of −0.56 to 0.78 log IU/mL. Quantifiable results with both the Roche and Abbott assays were obtained for 611 of the HCV positive clinical specimens. Linear regression analysis yielded a slope of 0.99 (95% CI: 0.98 to1.01), intercept of −0.25 (95% CI: −0.32 to −0.19), and R^2^ of 0.97 (Fig. [7](#Fig7){ref-type="fig"}). The slope and intercept were statistically significant (\<0.0001). By Bland-Altman analysis (Fig. [8](#Fig8){ref-type="fig"}), the average bias was −0.27 log IU/mL with 95% acceptability limits of −0.79 to −0.26 log IU/mL. A summary of the linear regression and bias calculations is shown in Table [7](#Tab7){ref-type="table"}.Fig. 3Method Comparison: Aptima vs Abbott. The figure shows results quantifiable in both the Aptima and Abbott assays in log IU/mL for 1058 HCV positive clinical specimens. Linear regression analysis yielded a slope of 1.06 (95% CI: 1.05 to 1.07), intercept of 0.08 (95% CI: 0.03 to 0.13), and R^2^ of 0.98 Fig. 4Bland Altman Plot: Aptima vs Abbott. The figure shows results quantifiable in both the Aptima and Abbott assays in log IU/mL for 1058 HCV positive clinical specimens. Bland-Altman analysis was conducted comparing the difference between the Aptima and Abbott assays against the average result for the two assays for each specimen. The average bias was 0.34 log IU/mL with 95% acceptability limits of −0.20 to 0.88 log IU/mL Fig. 5Method Comparison: Aptima vs Roche. The figure shows results quantifiable in both the Aptima and Roche assays in log IU/mL for 608 of the HCV positive clinical specimens. Linear regression analysis yielded a linear regression slope of 1.05 (95% CI: 1.03 to1.07), intercept of 0.12 (95% CI: −0.20 to −0.04), and R^2^ of 0.96 Fig. 6Bland Altman Plot: Aptima vs Roche. The figure shows results quantifiable in both the Aptima and Roche assays in log IU/mL for 608 positive clinical specimens. Bland-Altman analysis was conducted comparing the difference between the Aptima and Roche assays against the average result for the two assays for each specimen. The average bias was 0.11 log IU/mL with 95% acceptability limits of −0.56 to 0.78 log IU/mL Fig. 7Method Comparison: Abbott vs Roche. The figure shows results quantifiable in both the Abbott and Roche assays in log IU/mL for 611 HCV positive clinical specimens. Linear regression analysis yielded a slope of 0.99 (95% CI: 0.98 to1.01), intercept of −0.25 (95% CI: −0.32 to −0.19), and R^2^ of 0.97 Fig. 8Bland Altman Plot: Abbott vs Roche. The figure shows results quantifiable in both the Abbott and Roche assays in log IU/mL for 611 positive clinical specimens. Bland-Altman analysis was conducted comparing the difference between the Aptima and Roche assays against the average result for the two assays for each specimen. The average bias was −0.27 log IU/mL with 95% acceptability limits of −0.79 to −0.26 log IU/mL Table 7Parameters from Aptima, Abbott and Roche Method ComparisonsParameterAptima vs AbbottAptima vs RocheAbbott vs Rochen1058608611R^2^0.980.960.97slope1.061.051.0095% CI for slope1.04 to 1.071.03 to 1.070.98 to 1.01Intercept0.08−0.12−0.2595% CI for intercept0.03 to 0.13−0.2 to −0.04−0.32 to −0.19average bias0.340.11−0.2795% acceptability limits−0.20 to 0.88−0.57 to 0.79−0.79 to 0.25

Agreement at low HCV Concentrations {#Sec17}
-----------------------------------

Table [8](#Tab8){ref-type="table"} shows the agreement between Aptima and Roche results using 107 specimens that gave an HCV results \</= 25 IU/mL using the Roche assay. Positive agreement was 89% (47/53) and negative agreement was also 89% (48/54). Six specimens gave a positive result in the Aptima assay and a negative in the Roche assay (Table [9](#Tab9){ref-type="table"}). Sufficient volume was available to test four of the six discordant specimens using the Abbott assay. Two of the four gave detected but not quantifiable results in both Aptima and Abbott assays. The other two gave quantifiable results above 25 IU/mL in both Aptima and Abbott assays. There were six specimens that gave a positive result by Roche but a negative result by Aptima (Table [9](#Tab9){ref-type="table"}). All the Roche results were detectable but not quantifiable. Sufficient volume was available to test two specimens with the Abbott assay and both gave negative results.Table 8Agreement Between Aptima and Roche for Specimens at or Below 25 IU/mLAptimanegativepositivetotalnegative48654Rochepositive64753% Agreement89%89% Table 9Discordant Specimens at or Below 25 IU/mLAptima Log IU/mLAbbott Log IU/mLRoche Log IU/mL1.972.18TND2.642.59TNDDetect \<10 IU/mLDetectedTNDDetect \<10 IU/mLDetectedTNDDetect \<10 IU/mLNTTNDDetect \<10 IU/mLNTTNDNDTNDDetectedNDTNDDetectedNDNTDetectedNDNTDetectedNDNTDetectedNDNTDetectedKeyTND, Target Not DetectedND, Not DetectedNT, Not tested

Discussion {#Sec18}
==========

As recommended by CDC, AASLD/IDSA and EASL guidelines HCV NAAT can be used to confirm the presence of an active HCV infection or reinfection after previous viral clearance in patients with a positive HCV antibody result \[[@CR6], [@CR8], [@CR9]\]. Also, current testing guidelines recommend viral load testing with a HCV NAAT prior to initiating HCV therapy to determine the baseline viral load level and to monitor patients while on therapy as well as to detect a sustained virologic response. The data presented in this paper supports the use of the Aptima assay for these purposes.

To be effective as a diagnostic and viral load monitoring test a NAAT assay must quantitate HCV results across a wide dynamic range, be sensitive, specific, accurate, precise and quantify all 6 HCV genotypes similarly. Performance across a large dynamic range is important because HCV RNA levels can reach over 10,000,000 IU/mL \[[@CR12]\]. The linearity of the Aptima assay across a wide dynamic range is shown in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}. The correlation (R^2^) for samples diluted over a 7 log range in HCV concentration was 1.00. The intercepts for the linear plots were between −0.11 and 0.17 log IU/mL indicating little bias and good linearity.

The sensitivity of the Aptima assay in both serum and plasma is shown in Table [3](#Tab3){ref-type="table"}. Probit analysis to determine the LoD (95% positivity) of HCV genotypes 1--6 diluted into either serum or plasma showed an LoD of 5 IU/mL or lower in all genotypes. In addition, the LLoQ determined in serum and plasma for genotypes 1--6 was 10 IU/mL or lower. This level of sensitivity is important because the end point for therapy of HCV is defined as \</=25 IU/mL so an assay must be able to accurately quantitate at levels at or below 25 IU/mL \[[@CR8]\]. It is recommended by EASL that for HCV diagnosis, an assay with a lower limit of detection \< 15 IU/mL is used \[[@CR9]\]. It has also been suggested that testing HCV levels below 50 IU/mL with highly sensitive assays can detect more positive patients and that these patients are more likely to relapse \[[@CR13]\]. With a sensitivity of 10 IU/mL (LLoQ), the Aptima assay is able to quantify HCV at the levels needed for effective treatment monitoring and diagnostics.

Specificity is also important to avoid false positive results when diagnosing patients with HCV infections. As shown in Table [5](#Tab5){ref-type="table"} the specificity of the Aptima HCV was 100% for both serum and plasma specimens.

Sensitivity and specificity of the Aptima assay were further tested using 107 specimens that gave an HCV result \</=25 IU/mL using the Roche assay. As shown in Table [8](#Tab8){ref-type="table"}, positive and negative agreement between the Aptima and Roche assays was 89%. Four of the six samples negative by Roche and positive by Aptima, were also tested in the Abbott assay. Two of these were detected but not quantified by Abbott and Aptima. This indicates that these two specimens likely contained very low levels of HCV. However, the other two specimens tested by the Abbott assay, gave results well above the limit of quantitation (2.18 and 2.58 log IU/mL). These specimens gave results of 1.97 and 2.64 log IU/mL respectively with the Aptima assay. This confirms these two results as false negative results by the Roche assay supporting the superior sensitivity of the Aptima assay. There were six results where the Roche assay detected HCV but the Aptima did not. All six specimens gave detectable but not quantifiable results using the Roche assay. Of these six specimens, two had sufficient volume to test using the Abbott assay and both gave "not detectable" results. Data from testing specimens with HCV levels at or below 25 IU/mL suggests that the Aptima assay has better sensitivity than the Roche assay and equivalent or better specificity. The performance of the Aptima assay compared to the reported performance of the Roche and Abbott assays is summarized in Table [10](#Tab10){ref-type="table"}. Based on this data, it is expected that the Aptima assay should show better sensitivity and comparable precision when measuring low levels of HCV.Table 10Performance Summary of the Aptima, Roche and Abbott AssaysAssay95% Limit of Detection WHO standard^a^ (IU/mL)Lower limit of Quantitation (IU/mL)Linear Range (IU/mL)Precision (log SD)Aptima HCV Quant Dxplasma 4.3 serum 3.91010-100,000,0000.14 at 2.06 log IU/mL (115 IU/mL)Abbott RealTi*m*eplasma 10.5 serum 7.21210-100,000,0000.10 at 1.96 log IU/mL (91 IU/mL)Roche Ampliprep/ COBAS Taqman HCV test v2.0plasma 11 serum 121510-100,000,000\</= 0.09 at 2.48 log IU/mL (300 IU/mL)^a^Second standard NIBSC 96/798 used for Aptima and Abbott. The third Standard NIBSC 06/100 for Roche Data taken from Aptima (11), Roche \[[@CR14]\] and Abbott \[[@CR15]\] package inserts

Good precision is an important requirement for an assay used to monitor patients during treatment. A single HCV RNA measurement may be used to confirm that SVR has been reached. The data shown in Table [6](#Tab6){ref-type="table"} shows that the coefficient of variation for the assay is below 13.3% even down to 1.2 log IU/mL (16 IU/mL). This low variation gives a high degree of confidence that a single RNA measurement using the Aptima assay will provide a reliable result for determining SVR.

The method comparison between the Aptima and Abbott assays used 1058 specimens obtained from over 30 different countries and included genotypes 1--6 representing a highly genetically diverse population of HCV. Statistical analysis of this data set demonstrated a slope of 1.06, an intercept of 0.08 and a correlation of 0.97. The slope was statistically significant and was influenced by slightly higher results for the Aptima assay above 5.5 log IU/mL. Although statistically significant, the magnitude of the difference is not clinically significant. The method comparison between the Aptima and Roche assays used 608 specimens. The slope of the Aptima assay compared to the Roche assay was similar to that seen when comparing the Aptima assay with the Abbott assay (1.05 -- 1.06). However, the average bias of the Aptima assay by Bland Altman analysis was lower vs the Roche assay (0.11 log IU/mL) compared to the Abbott assay (0.34 log IU/mL). There were 611 specimens that gave quantifiable results with both the Roche and Abbott assays. A method comparison was conducted with these data and gave a slope of 1.00, an intercept of −0.25 log IU/mL and an average bias of −0.27 log IU/mL. All three assays gave similar HCV viral load results indicating that there is no need to re-baseline patients if switching to the Aptima assay from the Roche and Abbott assays.

Conclusion {#Sec19}
==========

The Aptima assay has excellent sensitivity, specificity and precision. It can measure HCV RNA levels over a large dynamic range. The close agreement to the Abbott and Roche assays suggests that a re-baseline of patients is not required when switching to the Aptima assay for HCV testing. The Aptima assay is an excellent candidate for the diagnosis of HCV and monitoring HCV viral load of patients on HCV therapy.

Additional file {#Sec20}
===============

Additional file 1:Method comparison Aptima Abbott Roche. Supplemental data for VJ publication. (ZIP 16232 kb)
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:   Transcription Mediate Amplification

WHO

:   World Health Organization
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